SUNSHINE BIOPHARMA'S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK
December 22 2020 - 8:00AM
InvestorsHub NewsWire
SUNSHINE
BIOPHARMA'S
CORONAVIRUS
TREATMENT
ANTICIPATED
TO BE EFFECTIVE
AGAINST THE NEW VARIANT IDENTIFIED IN THE UK
Montreal, Canada -- December
22, 2020 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc.
(OTC
Pink:
"SBFM"), a pharmaceutical company focused on the research,
development and commercialization of oncology and antiviral
drugs today
announced that its Anti-Coronavirus drug development
program is
unaffected by the recent discovery of a new strain of Coronavirus
in Southern England. The new strain appears to be
more easily transmissible due to a mutation in the Spike
Protein, the
crown-like structure on the surface of the virus which allows it to
gain entry into the host cell. Sunshine Biopharma's
Anti-Coronavirus compound, SBFM-PL4, acts on the Coronavirus
Papain-Like Protease (PLpro) which is a non-structural
protein encoded by the viral genome and synthesized by the hijacked
protein synthesis machinery of the host cell. Sunshine
Biopharma's SBFM-PL4 inhibits PLpro and arrests viral
replication. SBFM-PL4 is expected to
inhibit the PLpro of the UK variant just as well
as it does the original strain since the UK strain does not show any
mutations in the PLpro gene.
"Mutations in
PLpro
which could affect
the binding of SBFM-PL4 to PLpro would have to be in the essential
regions of PLpro and would likely be deleterious and
produce non-viable
virus particles," said Dr. Steve N. Slilaty,
CEO of Sunshine Biopharma.
About
Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives
of over 1.3
million people worldwide since it first
appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have
contracted the illness. On May 22, 2020, Sunshine Biopharma filed a
provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting
down the ability of the virus to multiply and cause illness.
Sunshine Biopharma
has since screened the library and identified a lead
Anti-Coronavirus compound (SBFM-PL4). The Company is currently
conducting a
series of in
vitro tests to
evaluate its specific inhibitory activity of SBFM-PL4 against the SARS-CoV-2
papain-like protease (PLpro), one of two Coronavirus
encoded proteases essential for viral replication. Following the
initial in
vitro studies,
SBFM-PL4 will be moved forward to the cell culture testing stage
and assessment in Coronavirus infected mice before entering human
clinical trials.
About
Sunshine Biopharma
In addition,
to working on the
development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests
conducted to
date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property
pertaining to Adva-27a.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in
our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many
factors including but not limited to general stock market
conditions. Reference is hereby made to cautionary statements set
forth in the Company's most recent SEC filings. We have incurred
and will continue to incur significant expenses in our expansion of
our existing as well as new service lines noting there is no
assurance that we will generate enough revenues to offset those
costs in both the near and long term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information:
Sunshine
Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com